623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12F.P. Lin, David M. Thomas, S. Chinchen et al.|Annals of Oncology|2024Cited by 1
636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudyBenjamin Y. Kong, David Goldstein, Frank Lin et al.|Annals of Oncology|2024Cited by 0